FOLH1 and pachyonychia congenita: Thus, PSMA-PET has improved specificity and sensitivity compared to standard imaging (CT, MRI, and bone scintigraphy), and also improves the detection of metastatic disease in biochemically recurrent PC with low serum PSA levels.